Current approaches in the treatment of Alzheimer's disease

被引:144
作者
Shah, Reena S. [1 ]
Lee, Hyoung-Gon [3 ]
Zhu Xiongwei [3 ]
Perry, George [2 ,3 ]
Smith, Mark A. [3 ]
Castellani, Rudy J. [4 ]
机构
[1] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA
[2] Univ Texas San Antonio, Coll Sci, San Antonio, TX USA
[3] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
[4] Univ Maryland, Div Neuropathol, Dept Pathol, Baltimore, MD 21201 USA
关键词
Alzheimer's disease; amyloid-beta; cholinergics; nerve growth factor; oxidative stress; statins; vaccine;
D O I
10.1016/j.biopha.2008.02.005
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The management of Alzheimer's disease (AD) has been a long-standing challenge and area of interest. Advances in knowledge of the pathogenesis of disease and an increase in disease burden have prompted investigation into innovative therapeutics over the last two decades. This article reviews the various treatments of AD including those targeted towards cholinergic deficiency, oxidative stress, the amyloid cascade, inflammation, and excitotoxicity. Second generation cholinesterase inhibitors remain the preferred therapy for early and intermediate AD while the glutamate antagonist, memantine, is also approved for advanced stages of disease. Antioxidants may delay disease progression, while data on other experimental therapies remain equivocal at best. Gene therapy directed at neurotropins is currently under investigation with some intriguing preliminary results; however, the number of patients examined is too few to be conclusive. Drugs directly targeting amyloid-beta, particularly the amyloid-beta vaccine, continue to be investigated and their forthcoming results are eagerly anticipated. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:199 / 207
页数:9
相关论文
共 144 条
[1]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[2]   Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies [J].
Alexander, GE ;
Chen, K ;
Pietrini, P ;
Rapoport, SI ;
Reiman, EM .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (05) :738-745
[3]  
*ALZH RES FOR, 2008, LY450139 ALZH RES FO
[4]  
*ALZH RES FOR, 2007, AAB001 ALZH RES FOR
[5]  
*ALZH RES FOR, 1925, DRUGS CLIN TRIALS
[6]   DO NONSTEROIDAL ANTIINFLAMMATORY DRUGS DECREASE THE RISK FOR ALZHEIMERS-DISEASE - THE ROTTERDAM STUDY [J].
ANDERSEN, K ;
LAUNER, LJ ;
OTT, A ;
HOES, AW ;
BRETELER, MMB ;
HOFMAN, A .
NEUROLOGY, 1995, 45 (08) :1441-1445
[7]   Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages [J].
Asuni, Ayodeji A. ;
Boutajangout, Allal ;
Scholtzova, Henrieta ;
Knudsen, Elin ;
Li, Yong Sheng ;
Quartermain, David ;
Frangione, Blas ;
Wisniewski, Thomas ;
Sigurdsson, Einar M. .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 24 (09) :2530-2542
[8]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[9]  
Becher B, 2000, GLIA, V29, P293
[10]   Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons [J].
Blesch, A ;
Conner, J ;
Pfeifer, A ;
Gasmi, M ;
Ramirez, A ;
Britton, W ;
Alfa, R ;
Verma, I ;
Tuszynski, MH .
MOLECULAR THERAPY, 2005, 11 (06) :916-925